Updated:
Evofem Biosciences
Evofem Biosciences, led by CEO Saundra Pelletier, is a publicly traded biopharmaceutical company commercializing Phexxi, a non-hormonal contraceptive.
Evofem Biosciences
Evofem Biosciences was founded in 1995 and is headquartered in San Diego. The firm went public in 2013 and operates as a commercial-stage biopharmaceutical company, distinct from a wealth-management entity. Its wealth origin, if any, is not publicly disclosed as a family office. The company's strategy centers on women's sexual and reproductive health, with a primary focus on developing and commercializing Phexxi, a non-hormonal contraceptive gel approved by the FDA in May 2020. Beyond contraception, Evofem has pursued expanded indications, including a phase 2 trial for HIV prevention (pre-exposure prophylaxis or PrEP) and a clinical trial for chlamydia/gonorrhea prevention, though the latter was terminated. The company's geographic footprint is primarily U.S.-focused, with regulatory and sales operations domestically. Per public filings, the firm has also entered into co-promotion agreements with companies like AMAG Pharmaceuticals (since acquired by Covis Pharma) to expand product reach. As a publicly traded entity, Evofem's capital structure includes equity financing, public offerings, and debt. The company had 54 full-time employees as of its 2023 annual filing. In late 2023, Evofem announced a partnership with Innovation Pharmaceuticals to explore co-development opportunities, but financial details were not disclosed. Per the firm's own communications, in March 2024, Evofem reported full-year 2023 net product revenue of $12.5 million for Phexxi, reflecting a commercial focus. Evofem's structural differentiator is its public-market status: it is not a family office but a biotech holding company, which means its governance follows SEC disclosure rules rather than private wealth management. The company's risk profile is tied entirely to drug commercialization and clinical trial outcomes, making it a speculative, event-driven equity rather than a diversified investment vehicle.
General information
Firm type
other
Year founded
1995
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Evofem?
Evofem Biosciences is a publicly traded company. Investment decisions, including capital allocation for R&D and commercial activities, are made by the board of directors and management team, led by CEO Saundra Pelletier. The company does not function as a family office; its operations are governed by SEC disclosure rules.
How does Evofem source proprietary deal flow?
Evofem sources deal flow through licensing agreements, partnerships, and co-promotion deals within the biotech and pharmaceutical sectors. For example, it has partnered with AMAG Pharmaceuticals for co-promotion of Phexxi (per SEC filing, 2020). The firm's pipeline includes in-licensed candidates, though it does not disclose a proprietary sourcing method.
Is Evofem structured as a single family office or does it operate more like a biotech firm?
Evofem is a publicly traded biopharmaceutical company, not a family office. Its structure includes a board of directors, executive team, and shareholders. The firm's primary business is drug development and commercialization, with no disclosed wealth management or family-office services.
Does Evofem participate in fund commitments or only direct deals?
Evofem does not participate in fund commitments as an LP. As a public company, its capital is raised through equity offerings, debt, and revenue from product sales. It engages in direct licensing and partnership deals for its pipeline assets.
What investment stages does Evofem typically target?
Evofem targets late-stage clinical and commercial-stage assets in women's health. Its lead product, Phexxi, is already FDA-approved and marketed. The company has sought to expand indications through phase 2 trials for HIV PrEP and a terminated chlamydia trial, but does not typically invest in early-stage research.
Which sectors does Evofem explicitly avoid?
Evofem focuses exclusively on women's sexual and reproductive health. It avoids oncology, cardiovascular, neurology, and other therapeutic areas. The company's pipeline is centered on non-hormonal contraception, infection prevention, and reproductive health, as stated in its public filings.
Where does the underlying wealth come from?
Evofem is a publicly traded company with no disclosed wealth origin tied to a family office. Its capital comes from public investors, institutional holders, and retail shareholders. The firm's ownership structure includes mutual funds and index funds, but no controlling family or individual is named in its most recent proxy statement.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: